Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition
Status:
Suspended
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Type 2 diabetes is common, increases in prevalence with age, and patients with diabetes have
an increased risk of cardiovascular disease. A relatively new cardiovascular medication
currently used for the treatment of heart failure in the United States inhibits an enzyme
that breaks down a variety of signaling hormones. This clinical trial tests if it may also be
a target for the treatment of diabetes by decreasing the breakdown of a hormone that
increases insulin release after a meal.